ArticleFrontiers in public health2026
Polypharmacy, multimorbidity, and socioeconomic inequalities in a Spanish region: a population-based cross-sectional study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polypharmacy is closely linked to multimorbidity in older adults, but its distribution may also reflect social inequalities in health. We aimed to describe pharmacological burden and multimorbidity among individuals with polypharmacy in La Rioja, Spain, and to examine their relationship with age, sex, and socioeconomic conditions. Methods: This retrospective cross-sectional study included all individuals in La Rioja, Spain, who met the operational definition of polypharmacy between January 1 and December 31, 2024. Polypharmacy was defined as the dispensing of five or more distinct ATC4 medication groups, each dispensed at least six times during the study period. Only publicly funded prescriptions dispensed in community pharmacies were considered. Sociodemographic and clinical data were obtained from electronic health records. Pharmacological burden was quantified as the number of distinct ATC4 groups dispensed per individual and categorized as 5, 6-9, and ≥10 groups. Results: Among 33,534 individuals with polypharmacy, 54.7% were women and the mean age was 73.9 years. The mean pharmacological burden was 7.07 ATC4 groups (SD 2.17), with 58.4% of participants receiving 6-9 groups. Burden increased with age and was higher among individuals with chronic conditions, particularly congestive heart failure, renal disease, peripheral vascular disease, myocardial infarction, and chronic pulmonary disease. Sex differences were modest. In contrast, socioeconomic differences were marked: 71.8% of participants belonged to the low socioeconomic group, which also showed the highest proportion of individuals receiving ≥10 ATC4 groups (14.9%), compared with the middle (9.2%) and high (8.0%) socioeconomic groups. The highest burdens were observed in very low-income individuals and lower-income pensioners. Conclusions: In this population-based study, pharmacological burden among individuals with polypharmacy was concentrated on older adults, those with multimorbidity, and socioeconomically disadvantaged groups. These findings support interpreting polypharmacy not only as an indicator of clinical complexity, but also as a socially patterned health phenomenon. Efforts to optimize medication use should therefore integrate both clinical and socioeconomic vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.